Last Price$318.9(2.6%)
Market Cap$173.1B
LTM NOPAT
$6,440.7M
NOPAT margin
19.3%
5Y avg: 26.3%
EPV as % of EV
58.1%
Market-Implied Value of Growth,
MIVoG as % of EV
41.9%
Discount rate
5.8%
Stock quality
6/10
Good
AMGN Earnings Power Value Model
| (USD M) | Mar'20 | Jun'20 | Sep'20 | Dec'20 | Mar'21 | Jun'21 | Sep'21 | Dec'21 | Mar'22 | Jun'22 | Sep'22 | Dec'22 | Mar'23 | Jun'23 | Sep'23 | Dec'23 | Mar'24 | Jun'24 | Sep'24 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTM Revenue % growth | 23,966.0 0.9% | 24,301.0 3.1% | 24,987.0 6.8% | 25,424.0 8.8% | 25,164.0 5.0% | 25,484.0 4.9% | 25,767.0 3.1% | 25,979.0 2.2% | 26,316.0 4.6% | 26,384.0 3.5% | 26,330.0 2.2% | 26,323.0 1.3% | 26,190.0 (0.5%) | 26,582.0 0.8% | 26,833.0 1.9% | 28,190.0 7.1% | 29,532.0 12.8% | 30,934.0 16.4% | 32,534.0 21.2% | 33,424.0 18.6% |
LTM NOPAT % growth | 8,293.8 N/A | 8,082.5 (2.5%) | 8,190.8 1.3% | 8,162.5 (0.3%) | 7,923.3 (2.9%) | 6,559.5 (17.2%) | 6,388.5 (2.6%) | 6,717.9 5.2% | 5,828.3 (13.2%) | 7,010.5 20.3% | 6,660.8 (5.0%) | 5,779.6 (13.2%) | 7,328.9 26.8% | 7,760.3 5.9% | 7,817.6 0.7% | 7,748.3 (0.9%) | 6,033.8 (22.1%) | 5,498.1 (8.9%) | 5,621.3 2.2% | 6,440.7 14.6% |
Discount rate | 3.3% | 3.3% | 3.3% | 3.5% | 4.2% | 4.0% | 3.9% | 3.8% | 4.6% | 5.1% | 5.6% | 5.8% | 5.4% | 4.9% | 5.8% | 5.4% | 5.5% | 6.1% | 5.4% | 5.8% |
| Earnings Power Value (EPV) | 249,848.7 | 243,863.7 | 249,216.3 | 235,867.8 | 189,535.5 | 165,638.3 | 163,395.5 | 176,023.3 | 125,882.9 | 137,744.3 | 119,978.3 | 100,503.8 | 135,113.4 | 158,417.8 | 135,205.4 | 143,132.4 | 108,773.7 | 90,470.7 | 103,314.1 | 111,370.5 |
Enterprise Value (EV) | 144,523.2 | 159,993.3 | 168,058.5 | 153,912.8 | 166,903.8 | 161,048.6 | 146,548.3 | 151,934.1 | 158,870.4 | 161,615.1 | 151,538.4 | 167,738.4 | 159,296.0 | 148,354.6 | 171,082.6 | 179,817.7 | 195,930.5 | 222,097.7 | 226,617.8 | 191,543.1 |
| Market-Implied Value of Growth (MIVoG) | (105,325.5) | (83,870.5) | (81,157.8) | (81,955.1) | (22,631.8) | (4,589.7) | (16,847.2) | (24,089.2) | 32,987.5 | 23,870.7 | 31,560.0 | 67,234.6 | 24,182.6 | (10,063.2) | 35,877.2 | 36,685.3 | 87,156.8 | 131,627.0 | 123,303.7 | 80,172.6 |
| EPV as % of EV | 172.9% | 152.4% | 148.3% | 153.2% | 113.6% | 102.8% | 111.5% | 115.9% | 79.2% | 85.2% | 79.2% | 59.9% | 84.8% | 106.8% | 79.0% | 79.6% | 55.5% | 40.7% | 45.6% | 58.1% |
| MIVoG as % of EV | (72.9%) | (52.4%) | (48.3%) | (53.2%) | (13.6%) | (2.8%) | (11.5%) | (15.9%) | 20.8% | 14.8% | 20.8% | 40.1% | 15.2% | (6.8%) | 21.0% | 20.4% | 44.5% | 59.3% | 54.4% | 41.9% |
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
AMGN NOPAT
Annual
Quarterly
LTM
AMGN Earnings Power Value and Enterprise Value
Annual
LTM
Enterprise Value Breakdown
EPV and MIVoG as % of EV
AMGN vs Peer Set: Earnings Power Value comparison
General
Earnings power value
Financial metrics
Company name
EPV as % of EV
MIVoG as % of EV
Revenue growth
EPS growth
Net income margin
Amgen Inc.AMGN
58.1%
41.9%
18.6%
(39.8%)
12.2%
Median Peer Set
67.7%
32.3%
7.8%
11.0%
14.4%
Pfizer Inc.PFE
122.7%
(22.7%)
8.8%
273.7%
12.6%
Merck & Co., Inc.MRK
104.9%
(4.9%)
6.7%
4,714.3%
26.7%
Novartis AGNVS
88.8%
11.2%
10.8%
(16.5%)
23.1%
Johnson & JohnsonJNJ
71.3%
28.7%
4.3%
(57.9%)
15.8%
Gilead Sciences, Inc.GILD
67.7%
32.3%
6.0%
(91.6%)
1.7%
Novo Nordisk A/SNVO
49.0%
51.0%
24.9%
142.8%
34.8%
AbbVie Inc.ABBV
43.6%
56.4%
3.7%
(11.4%)
7.6%
Eli Lilly and CompanyLLY
25.5%
74.5%
32.0%
102.4%
23.5%
AstraZeneca PLCAZN
23.1%
76.9%
18.0%
18.9%
13.0%
SanofiSNY
N/A
N/A
(3.8%)
3.1%
12.6%
Explore more intrinsic value tools hub for AMGN
Reverse DCF
Intrinsic Value
Peter Lynch Fair Value
Discount rate
Earnings growth model
Relative Value
DCF value calculator
Ben Graham Fair Value
Peter Lynch charts
Margin of safety
FAQ
What is Amgen Inc. Earnings Power Value?
As of Dec 31, 2024, Amgen Inc.'s Earnings Power Value is approximately $111.4B.
What is Amgen Inc. EV (Enterprise Value)?
As of Dec 31, 2024, Amgen Inc.'s Enterprise Value (EV) estimates at $191.5B.
What is Amgen Inc. NOPAT?
As of Dec 31, 2024, Amgen Inc.'s Net operating profit after tax (NOPAT) is approximately $6,440.7M.